# Clinical characteristics and preliminary retrospective evidence of adjunctive efficacy of intense pulsed light therapy for Demodex-associated blepharokeratoconjunctivitis: a single-center study

**Authors:** Shuo Yang, Ning Wang, Qingli Meng, Lin Lin, Lijuan Wang, Xiuming Jin

PMC · DOI: 10.1080/07853890.2026.2639675 · 2026-03-08

## TL;DR

This study shows that adding intense pulsed light therapy improves treatment outcomes for a type of eye inflammation caused by Demodex mites.

## Contribution

The study provides preliminary evidence that IPL therapy is an effective adjunct for treating Demodex-associated blepharokeratoconjunctivitis.

## Key findings

- IPL adjunctive therapy showed greater neovascularization regression and improved tear film stability.
- Patients with IPL had better visual acuity and lower recurrence rates compared to conventional treatment.
- Higher Demodex density correlated with more severe corneal lesions and worse meibomian gland dysfunction.

## Abstract

To characterize clinical features of Demodex blepharokeratoconjunctivitis (BKC) and evaluate the efficacy of intense pulsed light (IPL) adjunctive therapy.

Retrospective cohort study of 45 microbiologically confirmed Demodex-BKC patients. Outcomes were compared between conventional treatment (n = 35) and IPL-adjunctive groups (n = 10).

Corneal lesions predominantly involved the inferior cornea, with characteristic lid margin signs including cylindrical dandruff and recurrent chalazia. Significant diagnostic delays and frequent misdiagnosis were observed. Higher Demodex density strongly correlated with increased corneal lesion severity, central corneal involvement, and worse meibomian gland dysfunction. IPL adjunctive therapy demonstrated significantly superior outcomes versus conventional treatment: greater neovascularization regression, improved tear film stability, better visual acuity gain, and reduced 6-month recurrence. Treatment was well-tolerated without adverse events.

In this retrospective study, IPL adjunctive therapy was associated with improved clinical outcomes in Demodex-BKC, including reductions in mite burden, inflammation, and recurrence risk. These findings suggest it may represent a promising adjunctive therapeutic strategy.

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** ocular rosacea (MESH:D012393), pain (MESH:D010146), visual impairment (MESH:D014786), keratoconjunctivitis (MESH:D007637), Corneal lesion (MESH:D003316), telangiectasia (MESH:D013684), atopic (MESH:C566404), trauma (MESH:D014947), chronic inflammation (MESH:D007249), Ocular Surface Disease (MESH:D010534), inflammatory damage (MESH:D018746), PBKC (MESH:D063766), hyperemia (MESH:D006940), hypoxic (MESH:D002534), corneal infiltrates (MESH:D017254), hypoxia (MESH:D000860), keratoconjunctival disorders (MESH:D009358), ocular itching (MESH:D011537), viral keratitis (MESH:D014777), conjunctivitis (MESH:D003231), keratitis (MESH:D007634), keratopathy (MESH:C562399), corneal epithelial damage (MESH:D009375), phlebitis (MESH:D010689), eyelash loss (MESH:C536554), chalazia (MESH:D017043), Ulcerative (MESH:D014456), erosions (MESH:D014077), toxicity (MESH:D064420), neurovascular dysfunction (MESH:D013901), corneal epithelial defects (MESH:C536444), Demodex infection (MESH:D007239), MGD (MESH:D000080343), corneal involvement (MESH:C537363), hypersensitivity (MESH:D004342), corneal epithelial erosion (MESH:C565155), elevated (MESH:D006937), Blepharitis (MESH:D001762), infectious (MESH:D003141), eyelid abnormalities (MESH:D005141), tissue damage (MESH:D017695), corneal damage (MESH:D065306), ocular diseases (MESH:D005128), sex hormone deficiency (MESH:D058533), corneal ulceration (MESH:D003320)
- **Chemicals:** loteprednol (MESH:D000069559), chitin (MESH:D002686), fluorometholone (MESH:D005469), cedarwood oil (MESH:C042023), Tobramycin (MESH:D014031), cyclosporine (MESH:D016572), tacrolimus (MESH:D016559), oxybuprocaine (MESH:C005298), 4-terpineol (-), dexamethasone (MESH:D003907), tea tree oil (MESH:D020947), lipid (MESH:D008055), turpentine oil (MESH:D014425), steroid (MESH:D013256), ofloxacin (MESH:D015242), lotilaner (MESH:C000711088)
- **Species:** Bacillus subtilis (species) [taxon 1423], Fungi (kingdom) [taxon 4751], Homo sapiens (human, species) [taxon 9606], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus (genus) [taxon 1279], Demodex (genus) [taxon 188544]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12973792/full.md

---
Source: https://tomesphere.com/paper/PMC12973792